BioEcho develops single-spin and 96/384-well kits based on the proprietary single-step EchoLUTION nucleic acid extraction process. Highly superior to the commonly used Silica-based solutions (bind-wash-elute), the whole procedure is extremely fast. Washing steps are not required and the isolated inhibitor-free RNA/DNA is detected with increased sensitivity. Due to the expertise of its founders and employees, BioEcho also uses their know-how to support companies with limited research capacities or specialized scientific knowledge. Especially in times like these, BioEcho helps to accelerate accurate tests on certain RNA/DNA viruses or pathogens.
Newron terminates sarizotan development in Rett syndrome
Latest NewsNewron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Roche gets FDA okay for COVID-19 antibody test
Latest NewsRoche Diagnostics has received FDA Emergency use approval for its highly specific Elecsys antibody test.
BioEcho Focus on extremely fast DNA/RNA tests
Sponsored PublicationsBioEcho develops single-spin and 96/384-well kits based on the proprietary single-step EchoLUTION nucleic acid extraction process. Highly superior to the commonly used Silica-based solutions (bind-wash-elute), the whole procedure is extremely fast. Washing steps are not required and the isolated inhibitor-free RNA/DNA is detected with increased sensitivity. Due to the expertise of its founders and employees, BioEcho also uses their know-how to support companies with limited research capacities or specialized scientific knowledge. Especially in times like these, BioEcho helps to accelerate accurate tests on certain RNA/DNA viruses or pathogens.
European Biotechnology Guide 2020 goes digital
Sponsored PublicationsAdditional to the print edition the European Biotechnology Science & Industry Guide 2020 is available digital in the App Store and at Google Play. Download the free BIOCOM app on smartphone, tablet or laptop and have the complete edition in one hand.
Phages as a promising alternative to antibiotics
BackgroundAustrian Phagomed wants to close a Series A financing in 2020. The start-up is working on phage-based treatments as a new alternative to antibiotics.
From Novartis to Syncona
AppointmentsLondon-based Syncona Ltd announces the appointment of Danny Bar-Zohar as Syncona Partner, starting mid of April.
Bone Therapeutics bags €11m
Latest NewsBelgian Bone Therapeutics SA has secured €11m to foster development of its late stage pipeline candidates.
Cevec launches ELEVECTA platform
Latest NewsCevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
Artes enters COVID-19 vaccine race
Latest NewsGerman vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.
Bayer, Novartis, and Trump convicted by Nature
Latest NewsThe politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.